Actively Recruiting
Study of Oral Paclitaxel with Subcutaneous Pertuzumab and Trastuzumab as Pre-Surgery Treatment for HER2-positive Breast Cancer
Led by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Updated on 2026-04-29
112
Participants Needed
9
Research Sites
130 weeks
Total Duration
AI-Summary
What This Trial Is About
This research aims to study the effectiveness and safety of combining oral paclitaxel with a fixed-dose combination of pertuzumab and trastuzumab given as a subcutaneous injection for patients with HER2-positive breast cancer. The trial focuses on using this combination as neoadjuvant therapy, which is treatment given before surgery. The study design is a multicenter, single-arm trial using Simons two-stage method to evaluate this approach in patients with specific stages of HER2-positive invasive breast cancer. Participants will receive oral paclitaxel solution along with subcutaneous injections of pertuzumab and trastuzumab every three weeks for six cycles. The oral paclitaxel dose is 200 mgm2 taken twice daily on days 1, 8, and 15 of each 21-day cycle. Pertuzumab and trastuzumab are administered via subcutaneous injection starting with a loading dose of 1200 mg pertuzumab plus 600 mg trastuzumab, followed by maintenance doses every three weeks. After completing neoadjuvant therapy, all participants will undergo surgery according to local guidelines. During the study, participants will be monitored through various assessments including evaluation of the total pathological complete response after surgery, which will occur within six weeks following the neoadjuvant treatment. The trial also tracks overall response rate, event-free survival, overall survival up to three years, quality of life from baseline through 30 days post-treatment, and adverse events from the first dose until 30 days after treatment completion. The total participation period includes treatment cycles, surgery, and follow-up assessments to evaluate outcomes and safety.
CONDITIONS
Brief Title
Neoadjuvant Oral Paclitaxel Plus Subcutaneous Pertuzumab/Trastuzumab in Patients With HER2-positive Breast Cancer
Research Team
Q
Qiang Liu, PhD
Y
Yudong Li, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here